Patent · US Active

FGFR inhibitor for use in the treatment of hypophosphatemic disorders

US10028955B2 · kind B2 · utility

1Cited by

0References

6Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Michaela Kneissel · Basel, CH
Vito Guagnano · Basel, CH
Diana Graus Porta · Basel, CH
Simon Wöhrle · Wien, AT

Key dates

Filing date	Sep 22, 2016
Grant date	Jul 24, 2018
Priority date	—
Expiry date	Sep 22, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.